Clinical Trial Update: Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating JTX-8064 as monotherapy and with a PD-1 inhibitor in adults with advanced refractory solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• JTX-8064

Snippet

Sponsor: Jounce Therapeutics, Inc. | Conditions: Cancer | Phase 1, Phase 2 | Status: COMPLETED